174 related articles for article (PubMed ID: 30699147)
1. In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.
Minami T; Ishida W; Kishimoto T; Nakajima I; Hino S; Arai R; Matsunaga T; Fukushima A; Yamagami S
PLoS One; 2019; 14(1):e0210362. PubMed ID: 30699147
[TBL] [Abstract][Full Text] [Related]
2. Epinastine 0.05% ophthalmic solution in contact lens-wearing subjects with a history of allergic conjunctivitis.
Nichols KK; Morris S; Gaddie IB; Evans D
Eye Contact Lens; 2009 Jan; 35(1):26-31. PubMed ID: 19125045
[TBL] [Abstract][Full Text] [Related]
3. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis.
Trattler WB; Luchs J; Majmudar P
Int Ophthalmol Clin; 2006; 46(4):87-99. PubMed ID: 17060795
[No Abstract] [Full Text] [Related]
4. Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis.
Ogura N; Fujisawa K; Kato M
J Ocul Pharmacol Ther; 2024 Apr; 40(3):173-180. PubMed ID: 38150534
[No Abstract] [Full Text] [Related]
5. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Fujishima H; Ohashi Y; Takamura E
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of topical cyclosporine a 0.05%, cyclosporine a 2%, epinastine hydrochloride 0.05%, and prednisolone acetate 1% on allergic inflammation in an experimental allergic conjunctivitis model.
Semsettin B; Sinan E; Nigar V
Cornea; 2013 Nov; 32(11):1465-9. PubMed ID: 24055903
[TBL] [Abstract][Full Text] [Related]
8. Epinastine in the management of ocular allergic disease.
Friedlaender MH
Int Ophthalmol Clin; 2006; 46(4):85-6. PubMed ID: 17060794
[No Abstract] [Full Text] [Related]
9. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
[TBL] [Abstract][Full Text] [Related]
10. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
[TBL] [Abstract][Full Text] [Related]
11. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
Villareal AL; Farley W; Pflugfelder SC
Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
[TBL] [Abstract][Full Text] [Related]
14. Quantitative determination of epinastine in plasma by high-performance liquid chromatography.
Ohtani H; Kotaki H; Sawada Y; Iga T
J Chromatogr B Biomed Appl; 1996 Aug; 683(2):281-4. PubMed ID: 8891928
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
17. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats.
Ohtani H; Kotaki H; Sawada Y; Iga T
J Pharm Pharmacol; 1997 Apr; 49(4):458-62. PubMed ID: 9232548
[TBL] [Abstract][Full Text] [Related]
18. Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects.
Pradhan S; Abhishek K; Mah F
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1135-40. PubMed ID: 19630694
[TBL] [Abstract][Full Text] [Related]
19. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
Ousler GW; Workman DA; Torkildsen GL
Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
[TBL] [Abstract][Full Text] [Related]
20. Distribution to the skin of epinastine hydrochloride in atopic dermatitis patients.
Toyoda M; Nakamura M; Nakagawa H
Eur J Dermatol; 2007; 17(1):33-6. PubMed ID: 17324825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
